Evidence map›Paper›PMID 40298502›Full record

ArticleAntibiotics (Basel, Switzerland)2025

Persistence of Colistin Resistance and

Komei Kawano, Takayuki Masaki, Tatsuya Kawaguchi, Makoto Kuroda

Abstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Genomic Epidemiology of ESBL and Non-ESBL-ProducingAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Komei KawanoDepartment of Medical Technology, Faculty of Health Sciences, Kumamoto Health Science University, 325 Izumi-machi, Kita-ku, Kumamoto 861-5598, Japan.
Takayuki MasakiDepartment of Medical Technology, Faculty of Health Sciences, Kumamoto Health Science University, 325 Izumi-machi, Kita-ku, Kumamoto 861-5598, Japan.
Tatsuya KawaguchiDepartment of Medical Technology, Faculty of Health Sciences, Kumamoto Health Science University, 325 Izumi-machi, Kita-ku, Kumamoto 861-5598, Japan.
Makoto KurodaDepartment of Medical Technology, Faculty of Health Sciences, Kumamoto Health Science University, 325 Izumi-machi, Kita-ku, Kumamoto 861-5598, Japan.ORCID 0000-0002-0487-4405

Funding

Japan Agency for Medical Research and Development JP22fk0108666j0001JSPS KAKENHI JP20K07815Kumamoto Health Science University Special Fellowship P&P 2022-C-02
6 · The paper itself

Abstract

Colistin, a polymyxin antibiotic used as a last-resort treatment for serious infections, exhibits efficacy against multidrug-resistant organisms. Colistin-resistant bacteria limit the treatment options and increase the risk of untreatable infections. In this study, we investigated various antimicrobial-resistant

Indexed as

broilercolistinE. coliIncI2mcr-1ST1485zinc tolerance

Identifiers

PMID40298502
PMCPMC12024320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.